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Objectives: Low patency rates of saphenous vein grafts remain a major predicament in surgical revascularization.
We examined a novel expandable external support device designed to mitigate causative factors for early and late
graft failure.
Methods: For this study, fourteen adult sheep underwent cardiac revascularization using two vein grafts for each;
one to the LAD and the other to the obtuse marginal artery. One graft was supported with the device while the
other served as a control. Target vessel was alternated between consecutive cases. The animals underwent
immediate and late angiography and were then sacrificed for histopathologic evaluation.
Results: Of the fourteen animals studied, three died peri-operatively (unrelated to device implanted), and ten
survived the follow-up period. Among surviving animals, three grafts were thrombosed and one was occluded, all
in the control group (p = 0.043). Quantitative angiographic evaluation revealed no difference between groups in
immediate level of graft uniformity, with a coefficient-of-variance (CV%) of 7.39 in control versus 5.07 in the
supported grafts, p = 0.082. At 12 weeks, there was a significant non-uniformity in the control grafts versus the
supported grafts (CV = 22.12 versus 3.01, p < 0.002). In histopathologic evaluation, mean intimal area of the
supported grafts was significantly lower than in the control grafts (11.2 mm^2 versus 23.1 mm^2 p < 0.02).
Conclusions: The expandable SVG external support system was found to be efficacious in reducing SVG’s non-uniform
dilatation and neointimal formation in an animal model early after CABG. This novel technology may have the
potential to improve SVG patency rates after surgical myocardial revascularization.Background
Coronary artery disease (CAD) is the leading cause of
death worldwide [1]. The treatment of choice for patients
who suffer from severe CAD is coronary artery bypass
grafting surgery (CABG) in which the internal mammary
arteries (IMAs) and greater saphenous veins are utilized
as coronary conduits. While internal mammary arteries
carry gratifying long-term patency rates, vein graft failure
occurs in approximately 50% five to ten years after surgery
with evident atheroma in most of the remaining grafts
[2-5]. Although vein graft failure significantly increases pa-
tients’ risk of major adverse cardiac events (MACE) [6]
and may necessitate coronary re-interventions, the vast
majority of all conduits are still saphenous vein grafts
(SVG’s).* Correspondence: Mdbengal@gmail.com
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reproduction in any medium, provided the orWhile early vein graft occlusion is mainly due to tech-
nical aspects of the surgical procedure, intermediate and
late graft failure results from an irregular remodeling
and dilatation of the pressurized thin walled graft [7-9]
with subsequent intimal hyperplasia and wall thickening,
that reduces the graft’s luminal area and may promote
atheroma formation. These developments are thought to
be a consequential intrinsic adaptation of the thin walled
vein to arterial longitudinal, circumferential and pulsatile
flow and pressures [7,10,11].
The concept of external support for vein grafts has
been shown to be potentially effective in inhibiting
intimal-hyperplasia and wall thickening in several animal
studies [12-14]. Unfortunately, due to various technical
aspects, preclinical models or study design, this concept
has never been assimilated into daily clinical practice. In
this report we evaluated a novel expandable externall Ltd. This is an Open Access article distributed under the terms of the Creative
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factors for vein graft failure.
Methods
Fourteen mature female Assaf sheep weighting 60-80 Kg
form the basis of this study.
Surgical procedures were conducted at the Technion,
Israel Institute of Technology, Faculty of Medicine,
Haifa, Israel after obtaining approval from the institute’s
ethical committee for animal experiments. All proce-
dures complied with the Animal Welfare Acts of 1966
(P.L. 89–544), as amended by the Animal Welfare Act of
1970 (P.L. 91–579) and 1976 (P.L. 94–279) and after
obtaining approval from the institute’s ethical committee
for animal experiments.
The device we evaluated is made from braided cobalt-
chromium-nickel-molybdenum-iron alloy fibers, forming
an expandable external support apparatus (Fluent, VGS -
Vascular Graft Solutions, Tel Aviv, Israel). The aim of the
device is to provide vein grafts a shapeable, kink-resistantFigure 1 The compressed external support device. a: Expandable supp
on the vein graft after first anastomosis.tight external support, to prevent possible kinking, non-
uniform dilation, and wall thickening (i.e. intimal hyper-
plasia), factors known to cause early and late graft failure.
Briefly, a compatible device is threaded in a com-
pressed configuration over the vein graft, the device size
is determined by measurement of the vein diameter just
after harvest, while slightly inflated, and its length is de-
termined just after final trimming of the vein rim, prior
to performing the proximal aortic anastomosis (Figure 1).
The device is than stretched open manually and shaped
by the surgeon to cover the entire vein (Figure 2) while
the assistant-surgeon elevates and stabilizes the heart
with one hand and the proximal tip of the vein with the
other hand. The device’s proximal rim can be easily
shortened with surgical Potts scissors for slight differ-
ences between device and graft lengths. Final adjust-
ments of the device-graft arrangement are made as the
heart returns to its normal volume and position.
All animals were pretreated with buffered aspirin
(325 mg/d) and Clopidogrel (150 mg/d) 72 hours priorort device in its compressed configuration. b: The device is mounted
Figure 2 The stretched external support device. a: External support device in its stretched configuration; b: The device treaded open on the
vein graft after the second anastomosis.
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Clotting Time (ACT) was measured prior to the perfor-
mances of the first anastomoses and Heparin 5000 units
were administrated to all animals. Additional doses were
given to maintain ACT values above 300 seconds, until
completion of the surgical procedure. Heparin was not
reversed at the end of the procedure.
Animals were placed in dorsal recumbence, and the
saphenous vein was harvested through an uninterrupted
leg incision, its side branch closed with small size
hemoclips. A left lateral thoracotomy at the 3rd or 4th
intercostal space was performed with a 20–25 cm long
skin Incision with the LAD and larger obtuse-marginal
arteries identified following pericardial incision. In each
sheep, one vein graft was supported by the device and
the other vein graft served as a control, alternating in
every procedure, either to LAD or to the left circumflex
territories, so that after measuring and trimming both
grafts to the desired length, an appropriate device was
threaded over only one of the grafts. A stabilizer (Octo-
pus, Medtronic Inc. Minneapolis, MN, USA) was used
and grafts were then sutured to the coronary arteries
using a continuous 7/0 polypropylene suture. After
performing both anastomoses, the proximal coronary ar-
teries were ligated and the device manually stretched open
and shaped to cover the entire graft. The pericardium wasthen loosely reapproximated and the chest was closed
with no reversal of heparin. General anesthesia was termi-
nated and the sheep extubated upon resumption of vagal
reflexes.
Angiographic evaluation
Verification of graft patency and quantification of luminal
diameter was achieved by immediate post-procedural
angiography (t = 0) and at the end of the predetermined
follow up (t = 12 weeks post-procedure). Following cali-
bration relative to the 6 Fr diagnostic catheters, all graft
angiographic images were divided to seven equal sections,
in order to randomly measure the luminal diameters. Per-
centage coefficient of variance (%CV) was then calculated
for each graft to compare diameter variance of the grafts
at t = 0 and t = 12 weeks post procedure.
Histopathologic evaluation
Immediately following the second angiography (t = 12 weeks)
animals were sacrificed and grafts were harvested,
photographed and examined for inflammation, injury or
thrombosis (Table 1 and Figure 3). Grafts were than
washed with Dextrose 5% solution and pressure fixated
(100 mmhg) in 4% formaldehyde for 72 hours, cut and
prepared for standard paraffin (control graft) or plastic
embedment and sectioning (grafts with the device) and
Table 1 Histopathologic analysis
Experimental (supported) grafts Control grafts
Inflammation (>1) 0/10 (0%) 0/10 (0%)
Injury 0/10 (0%) 0/10 (0%)
Thrombosis 0/10 (0%) 3/10 (30%)
Injury (0–3)
0 = Tunica intima intact.
1 = Tunica intima lacerated, media compressed.
2 = Tunica intima lacerated, media lacerated, adventitia lacerated.
Inflammation (0–3)
0 = no inflammation.
1 = a very mild infiltration of few inflammatory cells (neutrophils/lymphocytes).
2 = moderate infiltration of > 10 inflammatory cells (neutrophils/lymphocytes).
3 = severe infiltration of > 100 inflammatory cells (neutrophils/lymphocytes).
Thrombosis
Organized thrombus in one or more cross section.
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first three animals, grafts had smeared layers with partially
or fully collapsed wall sections, prohibiting the collection
of reliable information. A new pressure fixation method
was then implemented on the following seven animals in
the study.
Cross- sections were then visualized with a BX51
microscope and thoroughly scanned using the Dotslide
2.1 virtual microscopy system (Olympus, Germany and
Japan). For each cross section, the lumen, neointima
and medial layers were identified and measured with the
Dotslide accompanying software. Five to seven cross sec-
tions in equal distances from proximal to the distal end
were analyzed from each vein, representing 100% of the
graft. Of note, plain determination of the average
neointimal area along the entire graft from all cross-
sections led to falsification of the true angiographic
Figure in relation to its possible clinical implications. For
example, a case of a distorted irregular graft with severe
concentric wall thickening and stenosis proximally, along
with significant remodeling and dilatation distally, would
be paradoxically interpreted as a “healthy” regular graft. InFigure 3 Autopsy documentation 3 months post implantation
(Close up sections are indicated with black arrows).order to interpret findings according to their true clinical
relevance, only the three cross sections with the most ex-
tensive neointimal area were compared between sup-
ported and control graft.
Statistical analysis
Due to the nature of the data collection and the desire
to demonstrate the effect of external support on the
morphology of vein grafts, it was decided to use a meas-
ure of variation. Since some correlation between mean
values and standard deviations for each graft was evi-
dent, it was decided to use the percentage % coefficient
of variation (%CV) as the parameter for the analysis.
Small %CV values imply that all measurements across a
vein are close to each other and thus good uniformity is
obtained. Large %CV values indicate large differences in
the diameter across the measured vein. This parameter
was selected also because either increase (remodeling
and dilatation) or decrease (intimal hyperplasia) in vein
diameter is possible. Non-parametric matched-pairs
(Wilcoxon Sign-Rank) test was used to compare the re-
sults from the externally supported and control vein
grafts.
Results
A total of four animals out of the fourteen expired dur-
ing the follow up period; three deaths occurred peri-
operatively and one death occurred three weeks after the
procedure. In all four we could not find any device-
related event as depicted in Table 2. No device-related
complications were noted up until the end of the prede-
fined follow-up period of three months. All together, six
sheep received the externally supported vein graft to
their LAD territory and a control (non-supported) vein
graft to their obtuse marginal (OM) coronary artery,
while four animals had an externally supported graft to
the OM and a control vein graft to the LAD. All sheep
underwent immediate post-operative angiographic evalu-
ation in an attempt to demonstrate the patency and in-
tegrity of supported and control grafts.
At the end of the three months follow up, a second
angiography demonstrated that all ten externally sup-
ported grafts were patent compared to nine of the con-
trol grafts. On this second angiographic evaluation, we
found stenotic lesions, occlusion or irregularities in none
of the externally supported grafts versus four of the non
supported control grafts, p = 0.043. In late angiography
we found no change in device position or in the extent
of graft coverage by the device.
Of note, one of the sheep had an aneurysmal dilatation
of the control (non-supported) vein at the end of the fol-
low up period, with normal appearance of the supported
vein. Regrettably, although both veins appeared quite or-
dinary during surgery (with photographic documentation)
Table 2 Cause of death
Time of death Cause of death Device related
Perioperative Animal expired while elevating the heart before any distal anasthomosis performed or device
implantation.
NO
perioperative Hemodinamyc collapse after post-operative angiography (both grafts patent By angioraphy and
PM) suspected narrowing in distal anastomosis of control-graft to LAD.
NO
perioperative Traumatic intubation and bleeding in the trachea, de-saturation during entire operation (60-80%),





Sudden death. PM demonstrated viable grafts, intact device and no gross pathologies. Microscopic
analysis demonstrated no injury or inflammation to both grafts.
NO
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ported vein during early angiography and it was therefore
excluded from angiographic analysis (Figure 4d).
Quantitative angiographic analysis of early and late
angiographic studies was performed (Figure 5) and coeffi-
cient of variance (%CV) was then calculated for each
graft’s luminal diameters immediately post surgery and at
three months of follow up. At t = 0, no significant variance
was found between the control and the externally sup-
ported grafts (%CV = 7.39 vs. %CV = 5.07, respectively, p
= 0.082). Twelve weeks after surgery the %CV in the
control grafts increased by 200% (CV%= 22.12) while in
the supported grafts CV% decreased by 40% (CV% =3.01,
p value < 0.002) representing significant lumen-uniformity
differences between the groups. (see Figures 4a-4d).
In gross pathology and histopathologic evaluation, all
grafts and anastomotic sites appeared to be normal, with no
apparent difference between grafts in terms of inflammatory
cell infiltration and intimal laceration (injury). In the exter-
nally supported group the graft’s adventitia was incorporated
into the device’s pores, fixated also by a thin layer of lucent
connective tissue (Figure 3) with no change of the device
position over the graft and without any detected breakage or
disintegration points of the device. The angiographic finding
of the single occluded control graft was confirmed, while
three other control grafts were found with an organized
thrombus in one or more cross-sections (Table 1).
Intimal hyperplasia: The measured neointimal area
on the histological slide was on average 100% greater
in the control grafts compared to the supported grafts
(23.056 mm2 vs. 11.196 mm2, p <0.02), with a mean
intimal thickness of 0.65 mm in the support group vs.
0.89 mm in the control group, p = 0.11 (Figure 6 illus-
trating the histologic appearance and analysis of con-
trol and externally supported grafts).
Media: The extreme thinness of the media layer and ir-
regular demarcation border with the neointima prevented
the extraction of data apart from the assumingly negligible
average media thickness of 0.07 mm for the supported
grafts vs. 0.25 mm for the control grafts p = 0.007. Lumen:
mean luminal-diameter was found to be 5.5 mm incontrol vs. 4.8 mm in supported grafts p = 0.21 but appro-
priate analysis of the lumen was difficult, due to the col-
lapsing layers in several histological sections.
To avoid bias of histopathologic results, we calculated all
parameters also after excluding the one sheep that had
aneurysmal dilatation of the control graft at the end of the
follow-up. Intimal area exclusive of the aneurysmal dilated
vessel was now 12.5 mm2 with the support versus
22.0 mm2 in the control vessels, p = 0.04 and intimal thick-
ness of 0.74 mm versus 0.95 mm respectively, p = 0.15.Discussion
As vein graft failure occurs in approximately 15-20%
during the first post operative year, late patency of SVGs
also remains poor at 50% with significant disease in
many of the remaining functional grafts [3]. Interfering
factors for early patency of SVG’s are kinks from exces-
sive graft length, tortuous pathway and poor surgical
and technical dexterity. Other factors are small target
vessel size with poor distal runoff, graft-to-coronary
diameter mismatch, competitive flow and general co
morbidities such as dyslipidemia, hypertension, diabetes
mellitus and smoking [3].
Intimal hyperplasia, namely the proliferation of
nonfunctional endothelial cells (poor production of nitric
oxide, adenosine and other vasomediators) and migration
of smooth muscle cells into the vessel wall, is eventually
the principal pathophysiological process leading to vein
graft failure [15-18]. This process is believed to be the re-
sult of the intrinsic adaptation to arterial pressures causing
cyclic stretching and increased wall tension of the graft,
along with trauma and oxidative stress associated with
vein harvest. The diameter mismatch and slow flow in the
graft compared to native coronary artery (Hagen-
Poiseuill’s law) results in low shear stress inside the vein
and promotes the neointimal proliferation [7]. Focal areas
of expansion or “remodeling”, further augment wall ten-
sion, intimal proliferation and impend laminar flow inside
the graft [8,9]. Later on, over-expression of adhesion mol-
ecules by the dysfunctional neointima causes monocyte,
Figures 4 Early and late post operative angiographic images. a-c: Angiographic images at t = 0 and at t = 12 weeks for supported and control vein
grafts; d: Angiographic image of a sheep with aneurysmatic dilatation of the control graft (marked in white arrow) and supported graft (marked in black
arrow) after 12 weeks (unfortunately, no angiographic images of the control graft were available for this sheep at t = 0).
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lipid-laden atherosclerotic plaque formation [2-5,19].
Since first hypothesized by Parsonnet et al. [12] several
studies evaluated the possible effect of various external
support models such as Dacron [20], polyglactin [21],
polyester [14], polytetrafluoroethylene [22], and Nitinol
[11] on saphenous vein grafts. These models demon-
strated that external reinforcement around saphenous
vein grafts may lessen intimal thickening and hyperpla-
sia. Unfortunately, due to various technical or methodo-
logical problems none of these external support models
was integrated into daily surgical practice.Additionally, porous external wrapping was shown to
promote significant peri-adventitial micro-vasculature, po-
tentially reducing the oxidative stress of the vessel wall
[10,21,23], and inversely associated with intimal thickness
[13,24]. The degree of constriction was also found to have
a possible effect on suppressing intimal hyperplasia [11]
and might be related to the symmetry imposed on the ves-
sel wall, enforcing laminar flow inside the graft, reducing
the wall tension (Laplace’s law) and the diameter mis-
match between the graft and the coronary artery.
In this report we describe the angiographic and histo-
pathological effect of a novel supportive device that was
Figure 5 Angiographic quantification of luminal dimensions in
seven sections equally distant from each other. Variance calculated
for each graft at t = 0 and at the end of the follow up (t = 12 weeks).
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intermediate vein graft failure: kink, torsion, asymmetric
dilatation-remodeling and the formation of thick ineffec-
tual neointima. This device is tangentially elastic and
un-kinkable but shapeable in its long axis to controlFigure 6 Histology images at 3 months. Histologic cross sections at t =
(6-b, 6-d).pathway and position of the graft. The device is deployed
in a slightly compressive manner, with no mounting ap-
pliances or adhesive materials.
With no immediate angiographic differences, after
three months the externally supported grafts maintained
their angiographic appearance and luminal regularity
(compared to initial angiography), while the control
grafts had an irregular appearance, with a significant
change in the luminal coefficient of variance. Three non
supported grafts had evident stenotic lesions (one graft
was occluded). In histopathologic analysis, no difference
between supported and control grafts was found in
terms of vessel wall trauma or inflammation; yet, sup-
ported grafts had a significantly smaller (approximately
50%) intimal area. Furthermore there was evident
thrombus formation within four of the controls versus
none in of the supported group.
This report has evident limitations with its sample
size and follow up period, but these are no different
than the other preclinical studies performed to evaluate
the role of external support on vein grafts. Several
years of follow up may be needed to fully demonstrate
the exact impact of external support on vein graft oc-
clusive disease. However, with the well defined infor-
mation on the pathological phases that cause vein graft
failure, adequate assumptions may well be made on12 weeks of the supported vein grafts (6-a, 6-c) and control graft
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ation of earlier (dilation-remodeling and intimal hyper-
plasia) occurrences, such as the differences we found
after three months of follow up. In addition, the major-
ity of the surviving animals that entered the angio-
graphic and histopathologic evaluation had the device
applied to the grafts anastomosed to the LAD (six out
of ten sheep), hence a potential difference may have
theoretically contributed to the different outcome be-
tween supported and non supported grafts due to pos-
sible dissimilarity in flow characteristics between
different coronary territories. Importantly, some covari-
ates (mainly technical), such as coronary target diam-
eter, angiographic appearance and vascular bed, were
not included in the analysis. These technical parame-
ters might affect progression of occlusive disease in the
both externally supported and control grafts. Finally,
this study’s animal (sheep) model or the abrupt occlu-
sion (ligation) that was inflicted on native coronary tar-
gets may not accurately reflect a human heart with
chronic atherosclerotic disease. Still, among recent
studies on venous external support, to our knowledge
only in the current study was an actual CABG model
actually used.
Despite the unprecedented success of CABG procedures
in the treatment of CAD, the main mitigating factor
against excellent long-term results remains poor vein-
graft patency rates. Vein-graft failure is a major cause for
repeated surgical procedures, PCI’s, hospitalizations and
other adverse events. However even with the growing
awareness and dedication of the surgical community to
using multiple arterial grafts, saphenous veins are, and will
continue to be in the foreseeable future, the predominant
grafts employed during surgical revascularization.Conclusions
Our current findings suggest that the expandable exter-
nal support device that was examined in a realistic sheep
model of surgical myocardial revascularization proved
efficacious in reducing vein graft irregularity and intimal
hyperplasia and may have the potential to improve pa-
tency and longevity of vein grafts deployed during clin-
ical coronary revascularization. In a further clinical
investigation, the first trial with this expandable support
system is currently being conducted in the UK, to deter-
mine the potential of this device in future surgical
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